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Background: The purpose of this work was to compare the efficacy of photodynamic therapy 
(PDT) with or without posterior subtenon injections of triamcinolone acetonide (STA) or 
  intravitreal injections of ranibizumab (IVR) for retinal angiomatous proliferation (RAP).
Methods: Thirty-seven eyes from 33 consecutive patients with RAP were treated by PDT 
monotherapy (Group 1), PDT combined with STA (Group 2), or PDT combined with IVR 
(Group 3). The best-corrected visual acuity, greatest linear dimension, central retinal thickness, 
and number of treatments were compared among the three groups.
Results: The change in mean best-corrected visual acuity (logMAR) at month 3, 6, and 12 
after the initial treatment was better in Group 2 (-0.13, -0.23, and -0.21, respectively) and 
Group 3 (-0.018, 0.0028, and -0.0067, respectively) than in Group 1 (0.13, 0.19, and 0.23, 
respectively); Group 1 versus Group 2 was statistically significant (P = 0.018). The mean cen-
tral retinal thickness was reduced from baseline in all groups, but the reduction amplitude was 
significantly greater in Group 2 than in Group 1 and Group 3. The mean number of treatments 
was significantly lower in Group 2 (1.1 ± 0.4) and Group 3 (1.5 ± 0.5) than in Group 1 (2.9 ± 0.9) 
in the 12 months after the initial treatment.
Conclusion: Treatment with STA + PDT may be an effective therapy for RAP lesions over   
12 months of follow-up.
Keywords: retinal angiomatous proliferation, photodynamic therapy, triamcinolone acetonide, 
ranibizumab, combined therapy
Introduction
Age-related macular degeneration (AMD) is a leading cause of central vision loss 
in the elderly in industrialized countries.1 The number of patients with AMD has 
increased remarkably over the years, and a further increase in patients with severe 
visual impairment due to AMD is anticipated.2 Advanced AMD is clinically classified 
into atrophic AMD and exudative AMD. Exudative AMD is further classified into 
typical neovascular AMD, polypoidal choroidal vasculopathy, and retinal angiomatous 
proliferation (RAP).1 These phenotypes are known to have different characteristics 
in their natural courses and their responses to interventions, such as photodynamic 
therapy (PDT) and antivascular endothelial growth factor (VEGF) therapy, although 
the reasons are unknown.3–5 Several studies have reported a poor response to PDT 
monotherapy in patients with RAP lesions.6,7 Hence, it is common to perform PDT 
combined with intravitreal injections of triamcinolone acetonide (IVT) or anti-VEGF 
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therapy for RAP.8,9 Several studies were conducted to address 
the comparative   effectiveness between PDT monotherapy 
and the combination of PDT with IVT or anti-VEGF therapy 
against RAP lesions, but their conclusions were not consis-
tent.10,11 Rouvas et al reported that IVT + PDT was more 
effective than intravitreal ranibizumab (IVR) + PDT for RAP 
lesions.10 In contrast, Saito et al reported that intravitreal 
bevacizumab + PDT was likely to be more effective than 
IVT + PDT in a Japanese RAP cohort.11 This discrepancy 
might reflect the different anti-VEGF agents used in the two 
studies, so more replication studies are needed.
A posterior subtenon injection of triamcinolone acetonide 
(STA) is an alternative method to deliver triamcinolone 
acetonide to the posterior retina. Although IVT may cause an 
elevation in intraocular pressure and cataracts as complica-
tions,12,13 STA might have fewer side effects in terms of induc-
ing intraocular pressure elevation or cataracts than IVT because 
STA should act on the retina transsclerally and thus affect the 
lens and trabecular meshwork less than IVT.14,15 However, to 
our knowledge, only a few published studies have compared 
the effectiveness of PDT combined with STA.13 Therefore, in 
this study, we performed a comparative assessment between 
STA + PDT, IVR + PDT, and PDT alone in RAP patients.
Subjects and methods
This study was approved by the institutional review board of 
the Kobe University Graduate School of Medicine, and was 
conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from all subjects. All 
cases in this study were Japanese individuals recruited from 
the Department of Ophthalmology at Kobe University   Hospital 
and Hyogo Prefectural Amagasaki Hospital in Japan.
This was a retrospective study of 37 eyes from 33 con-
secutive patients with RAP treated and followed up for more 
than 6 months. All patients received detailed ophthalmic 
examinations, including best-corrected visual acuity (BCVA) 
measurements, slit lamp biomicroscopy of their fundi, color 
fundus photography, fluorescein angiography, indocyanine 
green angiography, and optical coherence tomography. Visual 
acuities were determined using a Landolt C chart, and were 
converted to a logarithm of the minimum angle of resolution 
(logMAR) values for calculation. The diagnosis and staging of 
RAP was performed as previously described.16 Patients with 
past histories of retinal vessel occlusion, uveitis, rhegmatog-
enous retinal detachment, or glaucoma were excluded.
Fourteen eyes from 12 consecutive patients recruited by 
May 2006 were treated by PDT monotherapy (Group 1), 12 eyes 
from 10 consecutive patients recruited from June 2006 to March 
2009 were treated by PDT combined with STA (Group 2), and 
11 eyes from 11 consecutive patients recruited thereafter were 
treated by PDT combined with IVR (Group 3). No patients 
in this study received previous therapy except for one patient 
in Group 2 who underwent PDT monotherapy 4 months ear-
lier. For STA + PDT, a small incision was made in the lower 
temporal conjunctiva, and 20 mg of triamcinolone acetonide 
was injected retrobulbarly with a blunt needle 4–7 days before 
PDT. For IVR + PDT, 0.3 mg of ranibizumab was injected 
intravitreally with a 30-gauge needle 3–7 days before PDT. 
Patients were examined 3, 6, 9, and 12 months after the initial 
treatment, and were retreated if persistence or recurrence of 
intraretinal, subretinal, or subretinal pigment epithelium fluid, 
or any increase in retinal thickness was found by funduscopy 
or optical coherence tomography. The retreatment was done 
according to the same protocol as for the initial treatment.
For statistical analysis, we compared the gender, age, 
BCVA, greatest linear dimension, and central retinal thickness 
at baseline among the three groups. Changes in BCVA and 
central retinal thickness were then compared every 3 months 
until month 12 after the initial treatment. The number of treat-
ments performed during the first 12 months after the initial 
treatment was compared among the groups. To evaluate the 
influence of STA on intraocular pressure, intraocular pressure 
values before and 2 weeks after STA were measured for the 
STA + PDT group. The Wilcoxon signed-rank test was per-
formed to compare any two time points within the group and an 
analysis of variance was used to make a comparison between the 
groups. P values of 0.05 or less were considered to be statisti-
cally significant. StatView-J software (v 5.0; Abacus Corpora-
tion, Baltimore, MD) was used for statistical analyses.
Results
A summary of the data for the RAP patients is shown in Table 1. 
No differences were detected in baseline parameters between 
the three groups. The transition of values in mean BCVA 
(logMAR) and mean central retinal thickness are shown in 
Table 2. The change in mean BCVA at months 3, 6, and 12 
after initial treatment was better in Group 2 (-0.13, -0.23, 
and -0.21) and Group 3 (-0.018, 0.0028, and -0.0067) than 
in Group 1 (0.13, 0.19, and 0.23); Group 1 versus Group 2 
was statistically significant (P = 0.018, Figure 1). The mean 
BCVA was significantly better than baseline in Group 2 at 6 
and 12 months after the initial treatment (P = 0.012 and 0.025, 
respectively). In contrast, the mean BCVA in Group 3 had 
deteriorated by 12 months after the initial treatment, although 
it was not significant (P = 0.12). The mean central retinal 
thickness was reduced from   baseline after initial treatment in 
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all groups and the decrease was significant by 12 months in the 
STA + PDT and IVR + PDT groups   (Figure 2). The reduc-
tion amplitude was significantly greater in Group 2 than in 
Group 1 and Group 3 (P = 0.024 and P = 0.033, respectively, 
for Group 1 versus Group 2 and Group 2 versus Group 3). In 
the cases followed up for more than 12 months after initial 
treatment, the mean number of treatments was significantly 
lower in Group 2 (1.1 ± 0.4, n = 12) and Group 3 (1.5 ± 0.5, 
n = 9) than in Group 1 (2.9 ± 0.9, n = 14) over 12 months after 
initial treatment (P , 0.0001, P = 0.0004, and P = 0.15 for 
Group 1 versus Group 2, Group 1 versus Group 3 and Group 2 
versus Group 3, respectively, Mann–Whitney test) (Figure 3). 
In Group 2, the mean intraocular pressure before and after STA 
was 13.8 ± 3.4 mmHg and 16.8 ± 6.1 mmHg, respectively, 
(P = 0.18, two-tailed paired t-test). No ocular or systemic com-
plications were found or self-reported in the present cases.
Discussion
We compared the effects of PDT monotherapy, STA + PDT, 
and IVR + PDT in patients with RAP lesions, and found that 
the visual outcome was significantly better in those patients 
who underwent STA + PDT than in those treated with PDT 
monotherapy, although STA + PDT and IVR + PDT showed 
no significant difference in visual outcome. The mean num-
ber of treatments required per year was significantly lower 
in the STA + PDT and IVR + PDT groups than for the PDT 
monotherapy group. In addition, STA + PDT did not cause 
a significant elevation of intraocular pressure.
Currently, RAP is thought to be the most difficult subtype 
of exudative AMD to treat.7 Because previous studies have 
demonstrated an insufficient effect of PDT monotherapy 
for RAP lesions,6,7 most of the recent studies have focused 
on the effectiveness of PDT combined with IVT or anti-
VEGF therapy.8–11 However, few reports have evaluated 
the effects of STA + PDT for RAP. Montero et al reported 
that no better outcomes were observed in RAP patients 
treated with STA + PDT than in those treated with PDT 
monotherapy.13 They administered 40 mg of triamcinolone 
acetonide immediately after PDT, which resulted in no 
significant difference in outcomes as compared with PDT 
monotherapy. However, we used 20 mg of triamcinolone 
acetonide 4–7 days before PDT, and obtained significantly 
better outcomes as compared with PDT monotherapy 
in RAP patients. This difference might be due to the 
insufficient time for transscleral diffusion of triamcinolone 
acetonide when it was applied after PDT.14,15 Rouvas et al 
reported favorable outcomes for IVT + PDT when IVT was 
performed 7 ± 3 days before PDT.10 The mechanism by 
which triamcinolone acetonide works to improve the outcome 
of PDT is still a matter of speculation. An inflammatory 
response and upregulation of VEGF have been reported after 
application of PDT.17,18 Because triamcinolone acetonide has 
antiangiogenic, anti-inflammatory, and anti-VEGF effects,19,20 
the combination of PDT and triamcinolone acetonide may 
reduce the inflammatory response and upregulation of VEGF 
associated with choroidal neovascularization and PDT. 
Table 1 Baseline parameters of participants
Group 1 
(n = 14)
Group 2 
(n = 12)
Group 3 
(n = 11)
P value
Gender (male/female) 11/1 6/4 4/7 0.022†
Age (mean ± SD, years) 82.3 ± 4.1 78.2 ± 5.7 80.3 ± 7.2 0.10*
rAP stage 1 
Stage 2 
Stage 3
1 
6 
7
3 
4 
5
3 
5 
3
0.61†
GLD (mean ± SD) 4737 ± 1704 3948 ± 1238 3291 ± 1418 0.10*
Baseline BCVA logMAr (mean ± SD) 0.82 ± 0.47 0.78 ± 0.55 0.84 ± 0.37 0.84*
Notes: Group 1, PDT monotherapy; Group 2, STA + PDT; Group 3, iVr + PDT; *Kruskal–Wallis test; †Chi-square test.
Abbreviations: GLD, greatest linear dimension; BCVA, best-corrected visual acuity; PDT, photodynamic therapy; STA, subtenon injection of triamcinolone acetonide; 
iVr, intravitreal injection of ranibizumab; SD, standard deviation.
Table 2 Transition in best-corrected visual acuity and central 
retinal thickness of each group
Group 1 Group 2 Group 3
BCVA (logMAr) 
  Baseline 
  3 months 
  6 months 
  12 months
 
0.82 ± 0.47 
0.95 ± 0.36 
1.01 ± 0.31 
1.05 ± 0.32
 
0.78 ± 0.55 
0.66 ± 0.37 
0.56 ± 0.37* 
0.57 ± 0.35*
 
0.82 ± 0.38 
0.80 ± 0.44 
0.82 ± 0.40 
0.81 ± 0.42
CrT (μm) 
  Baseline 
  3 months 
  6 months 
  12 months
 
315 ± 93 
268 ± 104 
260 ± 93 
263 ± 84
 
358 ± 88 
204 ± 72* 
202 ± 84* 
241 ± 74*
 
314 ± 102 
211 ± 51* 
223 ± 51* 
202 ± 46*
Notes: Group 1, PDT monotherapy; Group 2, STA + PDT; Group 3, iVr + PDT; 
*P , 0.05 versus baseline.
Abbreviations: CrT, central retinal thickness; BCVA, best corrected visual acuity; 
PDT, photodynamic therapy; STA, subtenon injection of triamcinolone acetonide; 
iVr, intravitreal injection of ranibizumab.
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The significantly greater central retinal thickness reduction 
after STA + PDT than after IVR + PDT in the present study 
might reflect a difference in anti-inflammatory and anti-
VEGF effects between STA and IVR, which was possibly 
associated with the better outcome, although not significant, 
in the post-treatment BCVA for the STA + PDT group than 
for the IVR + PDT group. Although we performed IVR 
3–7 days before PDT, the timing of IVR might be too early 
because Debefe et al reported that ranibizumab should be 
administered within 24 hours after PDT in accordance with 
their experimental results.21 A recent report showed favorable 
visual outcomes after IVR + PDT when PDT was performed 
1–2 days after IVR.22 In addition, unlike previous reports, 
we did not add two extra monthly IVR after PDT in Group 3 
to save treatment costs, which might reduce the effect of 
IVR + PDT. However, the change in logMAR BCVA in 
Group 3 was almost equivalent to that of the previous report 
(0.02 between baseline and at least 6 months after the first 
therapy) performing three IVR + one PDT as an initial 
treatment.10 There is another possibility that the effects of 
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Figure 2 Changes in the CrT of rAP patients after PDT, STA + PDT, and iVr + PDT. Triangles with dashed line: PDT (Group 1); squares with solid line: STA + PDT 
(Group 2); diamonds with dot line: iVr + PDT (Group 3). 
Notes: Values represent mean ± SEM. *P , 0.05. **P , 0.05 between Group 1 and Group 2, or between Group 2 and Group 3.
Abbreviations: CrT, central retinal thickness; iVr, intravitreal injections of ranibizumab; rAP, retinal angiomatous proliferation; PDT, photodynamic therapy, STA, subtenon 
injections of triamcinolone acetonide.
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Figure 1 Changes in the BCVA of rAP patients after PDT, STA + PDT, and iVr + PDT. The BCVA was determined using the Landolt C chart, and is presented as decimal 
visual acuities. Triangles with dashed line: PDT (Group 1); squares with solid line: STA + PDT (Group 2); diamonds with dot line: iVr + PDT (Group 3). 
Notes: Values represent mean ± SEM; *P , 0.05 compared to baseline; **P , 0.05 between Group 1 and Group 2.
Abbreviations: BCVA, best corrected visual acuity; iVr, intravitreal injections of ranibizumab; rAP, retinal angiomatous proliferation; PDT, photodynamic therapy, STA, 
subtenon injections of triamcinolone acetonide.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
280
Nakano et alClinical Ophthalmology 2012:6
STA remained for several months after PDT and inhibited 
regrowth of neovascular tracts, reducing the number of 
treatments required to suppress the RAP lesions, and thus 
resulted in reduced cumulative retinal damage caused by 
PDT. Because a single STA is thought to have antiangiogenic 
and anti-inflammatory effects lasting up to 3 months23 while a 
single dose of IVR can work for a month, STA + PDT might 
have an advantage to suppress the RAP lesion longer than 
IVR + PDT. Conversely, IVR + PDT may necessitate some 
additional IVR during follow-up period.
Our results showed that the best mean BCVA was obtained 
at 6 months after the initial STA + PDT, but this was reduced 
by 12 months, mainly due to reactivation of RAP lesions 
in some cases. It is interesting that a reactivation of RAP 
lesions at 6 months after treatment was previously reported 
in cases treated with IVT + PDT.24 A previous review article 
mentioned that the best improvement in BCVA was achieved 
at 6 months after initial PDT + IVT, and that the effects faded 
by 12 months, with a high incidence of cataracts.9 However, 
in our study, no patient in the STA + PDT group showed 
any progression of cataracts during the follow-up period. In 
addition, the incidence of intraocular pressure elevation was 
reported less often with STA than with IVT.25
Currently, many treatment procedures are being tested 
and compared to establish the best strategy for treating RAP 
lesions. Among them, anti-VEGF therapy is the most investi-
gated modality which could be applied alone26,27 or combined 
with PDT.10,11,28 However, IVR + PDT is likely to be a very 
expensive therapy and intravitreal bevacizumab + PDT is 
not possible without off-label use of bevacizumab under cur-
rent circumstances. If STA + PDT showed similar or better 
outcomes to PDT+ anti-VEGF therapy or anti-VEGF mono-
therapy, there is a greater cost-effectiveness for patients. 
In fact, the improvement in BCVA (-0.22 ± 0.34 logMAR 
units) with STA + PDT in this study was almost equivalent 
to the average of previous reports (-0.17 ± 0.12 logMAR 
units) with anti-VEGF monotherapy.9,29
The major limitations of the present study were its non-
randomized and retrospective nature and the small number 
of subjects. Hence, it is important to evaluate the results of 
a randomized controlled trial for STA + PDT with a larger 
number of subjects to determine the efficacy of this therapy, 
particularly against RAP. Therefore, further investigation will 
be needed to determine the correct interventions for RAP.
In conclusion, STA + PDT may be an effective therapy 
for RAP lesions during the first 12 months after treatment, 
although the effects need to be further evaluated.
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